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Summary 
An RNA containing 2'-amino pyrimidines has been isolated using in vitro selection techniques 
that specifically and avidly (apparent Ka ,'-,30 nM) binds a mouse monoclonal antibody called 
MA20.  This 2'-amino-derivatized RNA is at least 10,000-fold more stable than unmodified 
RNA in serum, and can act as a decoy and block MA20 binding to its natural antigen, the hu- 
man  insulin  receptor,  on  lymphocytes.  Furthermore,  this  RNA  decoy can  inhibit  MA20- 
mediated downmodulation of insulin receptor expression on human lymphocytes in culture by 
up to 90%.  Surprisingly, the decoy RNA cross-reacts with autoantibodies from patients with 
extreme insulin resistance and can inhibit these antiinsulin receptor antibodies from downmod- 
ulating insulin receptor expression by up to 80% without impeding insulin binding to its recep- 
tor. These results suggest that in vitro--selected decoy RNAs may be able to specifically and 
selectively block oligoclonal autoimmune responses to self-antigens in patients with autoim- 
mune diseases. 
A 
utoimmune diseases are often caused by abnormal tar- 
geting of self-antigens by autoantibodies  (1).  A  small 
"decoy" ligand could potentially interrupt this process if it 
specifically and avidly bound the autoantibodies and blocked 
them  from interacting with  their target  antigen.  A  small 
peptide decoy seems the most obvious choice for such an 
inhibitor because a peptide should be  able  to structurally 
mimic the autoantigenic epitope on a self-protein. Unfor- 
tunately, isolation of small peptides that bind avidly to tar- 
get proteins has been difficult, probably because short pep- 
tides cannot adopt stably folded structures very readily (2). 
By contrast,  short RNA  molecules can form fairly stable 
structures through basepairing interaction (3), and RNA de- 
coys have been reported that avidly bind and block a vari- 
ety of  proteins (4-22). Expression of TAR and RRE decoy 
RNAs has been shown to render CD4 + T  cells resistant to 
HIV replication by inhibiting the functions of the RNA- 
binding proteins tat and rev (8-12). Furthermore, by using 
in vitro selection techniques, "designer" decoy RNAs have 
been isolated from large pools of random RNA molecules 
that bind with high affinity and specificity to several pro- 
teins,  including a few that  do  not naturally interact with 
nucleic acids  (13,  15-22). 
We  previously identified  a  designer  decoy RNA  that 
binds and blocks the mAb, MA20 (18).  This antibody nat- 
urally recognizes the  main  immunogenic  epitope  on  the 
human  insulin  receptor (23)  that  elicits  autoantibodies  in 
patients with severe insulin resistance (type B) (24-26). A1- 
though this RNA was  shown  to be able to block MA20 
binding to purified insulin  receptors in  solution in  a  test 
tube, we realized that the therapeutic utility of such a de- 
coy RNA  would  be  limited  by its  short  half-hfe in  the 
presence of serum nucleases. In addition, it was unclear if 
an RNA decoy made against  MA20 could block an oligo- 
clonal autoantibody response to the immunogenic epitope 
on the insulin receptor. Therefore, we sought to isolate a 
nuclease-resistant  decoy RNA  specific for MA20  and  to 
determine if this RNA could inhibit patient autoantibodies 
from binding the insulin receptors on human cells in culture. 
To generate nuclease-resistant RNA decoys, in vitro se- 
lection was performed using an RNA library that contains 
2'-amino-modified pyrimidine nucleotides. Changing the 
2' position on the pyrimidines of an RNA from a hydroxyl 
to  an  amino  group  substantially  increases  the  stability  of 
RNA in serum (27).  The modified pyrimidine nucleotides 
are compatible with in vitro selection procedures because 
2'-amino-2'-deoxypyrimidine triphosphates can be incor- 
porated  into  RNA  by  T7  RNA  polymerase  (28),  and 
RNA with 2'-amino pyrimidines can serve as substrates  for 
AMV  reverse  transcriptase.  Using  similar  methodology, 
RNase-resistant ligands with 2'-amino pyrimidines that bind 
human neutrophil elastase  (17,  20), basic fibroblast growth 
factor (21),  or vascular permeability factor/vascular endo- 
thelial growth factor (22) have been identified. 
Here, we report the isolation of a nuclease-resistant de- 
coy RNA that specifically and avidly binds the MA20 anti- 
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with  severe  insulin  resistance.  Furthermore,  the  decoy 
RNA  can  block  MA20  and  patient  autoantibodies  from 
binding to  and downmodulating expression  of insulin re- 
ceptors on human lymphocytes in culture without imped- 
ing insulin binding. 
Materials and Methods 
Antibodies  and Cells.  An  mAb,  MA20,  was  kindly provided 
by Ira Goldfine and Betty Maddux (University of California, San 
Francisco, CA). An mAb, 83-7, was a gift from Kenneth Siddle 
(Addenbrooke's Hospital, University of Cambridge, Cambridge, 
UK). Serum samples from three patients with severe insulin resis- 
tance  type B,  called B7,  B10,  and Bd,  were  provided by Do- 
menico Accili and Simeon Taylor (National Institutes of Health, 
Bethesda,  MD).  IM-9  human lymphoblasts (ATCC  159-CCL) 
express  high  levels  of insulin receptors  on their  plasma  mem- 
branes (29) and were used in insulin receptor downregulation ex- 
periments. 
Selection Procedure.  A  random pool of RNA oligonucleotides 
was generated by in vitro transcription of synthetic DNA tem- 
plates using 2' amino derivatized CTP and UTP (Amersham, Ar- 
lington Heights, IL) and normal GTP and ATP in the reaction. 
The sequence of the resulting RNA is 5'-GGGAGAGCGGAA- 
GCGUGCUGGGCCN40CAUAACCCAGAGGUCGAUGGA- 
UCCCCCC-3', where N40 represents 40 nucleotides (nts) 1 with 
eqimolar incorporation of A, G, C, and U  at each position. First, 
the RNA library (30 Ixg) was incubated with 5 txl normal mouse 
IgGs (1 mg/ml) in 100 txl binding buffer (30 mM Tris-HC1, pH 
7.5, 150 mM NaC1, 10 mM MgC12, 2 mM dithiothreitol, and 1% 
BSA) for 30 min at room temperature with shaking. Then, 20 p~l 
of goat  anti-mouse  IgG-coated  magnetic  beads  (Dynal,  Oslo, 
Norway) or 20 fxl of protein G-Sepharose beads (Pharmacia Bio- 
tech, Piscataway, NJ) were added to the binding reaction and in- 
cubated  for  an  additional 30  rain.  Antibody-RNA complexes 
were  immunoprecipitated and discarded to  remove  RNAs  that 
bind to the constant region of the antibodies or adhere nonspecif- 
ically to the beads. The precleared supernatant was transferred to 
a new tube and incubated with 5  txl of mouse mAb MA20 (0.5 
mg/ml) for 30 min at room temperature. The mAb-RNA com- 
plexes  were  then immunoprecipitated using magnetic beads  or 
protein G-Sepharose beads as mentioned above, and the pellets 
were washed three times with 0.5 ml of the binding buffer. RNA 
was eluted from the pellets by a 5-min incubation with 100 btl of 
0.1  M  EDTA and phenol extraction. The RNA eluate was then 
applied to a Sephadox G-50 spin column to remove EDTA and 
salts, and reverse-transcribed for 30 min at room temperature us- 
ing avian myeloblastosis virus reverse  transcriptase  (RT;  Boeh- 
ringer Mannheim, Indianapolis, IN)  and a  28-nt DNA  primer 
complementary to  the fixed 3' sequence of the RNA pool. The 
RT was then inactivated by heating the sample to 95~  for 5 min. 
The resulting cDNAs were amplified by PCR for 20 cycles using 
Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT) and a 
second DNA primer which was identical to the fixed 5'-end of 
the RNA pool and contained the  17-nt promoter sequence for 
T7 RNA polymerase. The amplified DNA was phenol extracted, 
ethanol  precipitated,  and resuspended in 25  I~1 of TE  (10  mM 
Tris-HCl, pH 8.0, 1 mM EDTA). 40% of this DNA template was 
t Abbreviation used in this paper: nts, nucleotides. 
transcribed in vitro with T7 RNA polymerase and the 2'-amino- 
modified mix of NTPs to generate RNA for the next round of 
selection. Subsequent rounds were performed in the same man- 
ner using either 50% (rounds 1-9) or 20% (rounds 10-12) of the 
transcribed RNA. Goat anti-mouse IgG-coated beads were used 
on odd-numbered and protein G-Sepharose beads on even nun> 
bered rounds of selection. From round 10, MA20 concentration 
was reduced fivefold, and mAb-RNA pellets were washed five or 
more times. After 12 rounds of selection, the amplified DNA was 
cloned and several clones were sequenced. 
Analysis of Selected RNAs by Immunoprecipitation.  Plasmid  DNA 
encoding 2'-amino RNA No.  1 was transcribed with T7 RNA 
polymerase  and  the  2-amino pyrimidine mix  of NTPs  in  the 
presence of [ec-32p]ATP  (Amersham). Transcribed RNA was gel 
isolated and purified RNA incubated with different antibodies in 
100 p~l of binding buffer for 30 min at room temperature. Anti- 
body-RNA complexes were  imnmnoprecipitated by goat  anti- 
mouse IgG magnetic beads or protein G-Sepharose beads.  The 
immunoprecipitates were washed three to five times with 0.5 ml 
of binding buffer. Bound RNA was eluted by addition of 15 b~l 
of 0.1 M EDTA and phenol extraction, and was analyzed on a 6% 
polyacrylamide gel with urea. 
Gel Shift Analysis of RNA-Antibody  Complexes.  Radiolabeled 
2'-amino RNA  No.  1  was  incubated with  MA20  in  binding 
buffer at room temperature for 30 min. The binding reaction was 
then mixed with one sixth of its volume of loading buffer con- 
taining 30%  glycerol.  Then  the  sample  was  loaded  onto  a  4% 
nondenaturing polyacrylamide gel containing 1 ￿  TBE buffer, 10 
mM  MgC12,  and  2%  glycerol.  Electrophoresis  was  performed 
with 0.5￿  TBE buffer at 4~  for 4 h. 
RNA Stability  Analysis in Serum.  10 nmol of 32p-body-labeled 
2'-amino RNA No. 1 was incubated in 200 b~l of 10% human se- 
rum or 10% fetal bovine serum at 37~  Aliquots of the mixture 
were removed at various times, quenched with 0.5 M EDTA and 
forrnamide, and analyzed on a 10% polyacrlyamide gel with urea. 
Measurement  of Antibody  Binding  to  Insulin  Receptors  on  IM-9 
Cells.  IM-9  cells  (5  X  104  )  were  washed  on  ice  in  FACS  | 
buffer  (PBS,  1% BSA,  0.1%  sodium azide)  containing 10  mM 
MgC12 and then resuspended in 100 I~l FACS  |  buffer containing 
10 mM MgC12 with normal nmuse IgG (isotype control, 50 ng), 
MA20 (50 rig), or 83-7 (3 p~l) preincubated with or without pool 
RNA (10 I'M) or selected RNA (10 btM).  After a 20-rain incu- 
bation on ice,  ceils  were  washed once with  FACS  |  buffer and 
stained  with  either  a  PE-conjugated  F(ab')  goat  anti-mouse 
IgG2b  antibody (Southern  Biotechnology Associates,  Birming- 
ham,  AL) for MA20  containing samples  or a  FITC-conjugated 
F(ab')  donkey  anti-mouse IgG antibody (Jackson  ImmunoRe- 
search Laboratories, West Grove, PA) for 83-7-containing sam- 
pies.  Next, cells were washed with FACS  |  buffer and then fixed 
with  FACS  |  buffer containing 0.4%  paraformaldehyde.  Stained 
cells were analyzed on a FACScan  |  apparatus (Becton Dickinson 
&  Co.,  Mountain View,  CA).  Results  were  displayed  as  fre- 
quency distribution histograms of log fluorescence. 
Monitoring  Insulin  Receptor  Downmodulation  on  IM-9  Cells. 
Insulin receptor  downregulation was assayed  as described previ- 
ously (23),  with a few modifications. 1.0  X  104 IM-9 cells were 
resuspended in 75 ILl of media (DMEM) with 10 mM MgC12, 1% 
BSA,  and  10%  FBS. MA20  (1  riM),  autoantibodies or insulin 
(1  p~M) were incubated in 25 >1 binding buffer with the original 
amino RNA pool,  2'-amino RNA  No.  1,  or no RNA  ~br 3{) 
min at  room temperature.  These  mixtures were  then  added  to 
IM-9 cells and incubated at 37~  for 15 min. Next, the cells were 
washed twice with a  phosphate buffer,  pH  6.0,  containing 154 
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tor-bound  ligands  (23).  To quantitate  the number  of insulin re- 
ceptors remaining on the cell surface, the cells were resuspended 
in 100 p~l of 100 mM Hepes buffer, pH 7.8, containing 120 mM 
NaC1,  1.2 mM MgSO4,  1 mM EDTA,  15 mM sodium acetate, 
10 mM glucose, and 1% BSA, and incubated with 150 pM 12sI-insu- 
lin for 70 min at 15~  The cells were pelleted and washed twice 
with 10 mM Tris-HC1 buffer, pH 7.8, containing 154 mM NaC1 
at 4~  The washed cells were pelleted again and the radioactive 
12sI-insttlin bound to them was determined using a "/5,000 counter 
(Packard  Instruments,  Meriden,  CT).  Incubation  of IM-9  cells 
with 1 nM of MA20 by itselfreproducibly reduced insulin recep- 
tor expression by '--~50% (data not shown).  This level of antigenic 
downregulation  was  considered  100%,  and  other  values  were 
normalized to this amount. Because 10 mM MgC12 is optimal for 
the binding of the selected RNA  to MA20 in vitro, cell culture 
experiments were performed in media containing 10 mM MgC12. 
For antigenic downregulation  experiments involving patient au- 
toantibodies,  patient serum or insulin was added to IM-9 cells at 
concentrations determined to engender similar levels of antigenic 
downregulation as  1 nM ofMA20:1  Ixl of a 1:25 dilution of B7, 
1 ILl of a 1:12 dilution of B10,  1 ~1 of undiluted Bd sera,  or 1 ~M 
of insulin (data not shown). 
Results 
Isolation  of Nuclease-resistant  RNAs  That  Specifically  Bind 
the MA20 Antibody.  An  RNA  library  of N1014  different 
molecules  was  generated  with  every pyrimidine  modified 
at its 2' position by an amino group.  Each molecule in the 
library  contained  a  40-nt  long region  derived from  a  ran- 
dom  sequence  flanked  by  defined  sequences.  The  amino- 
derivatized  RNA  library  was  preincubated  with  normal 
mouse  IgGs,  and  RNA-antibody  complexes  immunopre- 
cipitated and  discarded.  The precleared amino-RNA  pool 
was then incubated with the mouse mAb MA20, and RNA- 
antibody complexes immunoprecipitated. Bound RNAs were 
eluted  and  reverse transcribed.  The  resulting  cDNAs  were 
amplified  by  PCR  and  transcribed  to  generate  RNA  for 
the next cycle of selection. After 12 rounds  of selection (see 
Materials  and  Methods  for  details),  the  amplified  cDNAs 
were cloned, and  18  different clones sequenced. 
Three  different  RNAs  were  selected  that  specifically 
bind  the  variable  region  of the  MA20  mAb  (Fig.  1).  As 
shown  in  Fig.  1  A,  all  the  RNAs  were  6  nts  shorter  than 
the original 92-nt-long pool RNAs.  This  change probably 
resulted from deletion of part  of the random  region during 
reverse  transcription  and  PCR  amplification.  In  addition, 
the  three  RNAs  have  very  similar  sequences  and  were 
found  in  multiple  clones.  Interestingly,  the  sequences  of 
these  U-amino  derivatized  RNAs  (2'-amino  RNAs)  are 
very  different  from  the  sequences  of unmodified  RNAs 
that we previously generated to bind MA20  (18).  2'-amino 
RNA  No.  1  was  chosen  for  further  characterization  be- 
cause  it appeared  most frequently in the  sequenced  clones. 
To determine if2'-amino  RNA  No.  1 binds  specifically to 
the  MA20  antibody,  an  immunoprecipitation  experiment 
was performed using internally radiolabeled RNA.  The se- 
lected RNA  was shown  to bind only MA20  and  not other 
Figure 1.  Selected 2'amino RNA sequences and their specific binding 
to the mAb MA20. (A) After 12 rounds of in vitro selection, the sequence 
of 18 selected RNAs was determined,  and all were found to contain  34- 
nt-long  inserts.  Only  three  different  but  very similar RNA sequences 
were found in these clones, with each being present multiple times (num- 
bers in parentheses). Only two nucleotides  near the 3'-end of the inserts 
varied. The line drawn  for sequences Nos. 2 and 3 indicates that nucle- 
otides found at these positions are identical to those shown  for sequence 
No. 1. C and U in this figure correspond to U-amino C and U-amino U. 
(B)  2'-amino RNA No.  1 specifically binds  MA20.  Internally  radiola- 
beled RNA No. 1 (lanes 1-7, 2.5 nM) or original pool RNA (lanes 8-11, 
2.5 nM) was incubated  without any antibodies (lanes 2, 5, and 9) or with 
either normal mouse IgGs (lanes 3, 6, and  10, 100 nM) or the MA20 an- 
tibody  (lanes 4,  7,  and  11,  100  nM).  The  antibody-RNA  complexes 
were immunoprecipitated  with protein G-Sepharose  beads (lanes 2-4 and 
9-1 I) or goat anti-mouse IgG magnetic  beads (lanes 5-7).  lmmunopre- 
cipitated  RNAs were extracted  and  electrophoresed  in a 6% polyacryl- 
amide  gel with  urea.  Lanes  1 and  8  contain  20%  of the input-labeled 
RNA No.  1 or pool RNA,  respectively.  (C)  Formation  of 2'  amino 
RNA No.  1 and  MA20 antibody  complexes  can  only be inhibited  by 
specific RNA competitors.  Internally radiolabeled U-amino RNA No. 1 
(100 pM)  was incubated  without antibody  (lane 1), with normal  mouse 
lgGs (lane 2, 20 nM),  or with the MA20 antibody  (lanes 3-5,  20 nM). 
Antibody-RNA complexes were separated from unbound RNA in a 4% 
nondenaturing  polyacrylamide gel. The original pool RNA (lane 4, 1 p~M 
unlabeled) or U-amino RNA No. 1 (lane 5, 1 &M unlabeled) were added 
in a 10,000-fold excess to the binding reaction to determine if either could 
inhibit the formation of the 2'-amino RNA No. 1-MA20 complex. 
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pendent of the  type  of beads  used  to  immunoprecipitate 
the  MA20-RNA  complexes  (Fig.  1  B).  In addition,  the 
2'-amino  pool  RNA  does  not  nonspecifically bind  to 
MA20 (Fig. 1 B, lanes 8-11). 
To confirm that 2'-amino RNA No.  1 specifically binds 
the MA20 antibody, a gel retardation assay was developed. 
As shown in Fig.  1  C,  2'-amino RNA  No.  1  efficiently 
forms a "shifted" nucleoprotein complex with MA20, but 
not with normal mouse IgGs. Formation of this nucleopro- 
tein complex can be blocked by addition of a  10,000-fold 
excess  of unlabeled 2'-amino RNA  No.  1,  but not by a 
nonspecific competitor, such as the original 2'-amino pool 
RNA (Fig. 1 C, lanes 4 and 5). 
As a working model, the most stable secondary structure 
of 2'-amino RNA  No.  1 was  predicted using the  MUL- 
FOLD  program  (30),  and  is  shown  in  Fig.  2  A.  In  this 
folded  structure,  the  34-nt-long sequence,  derived  from 
the randomized region of the RNA library, is predicted to 
form  basepairing interactions with  the  defined sequences 
that flank the random region in the 2'-amino RNA pool. 
To begin to test the validity of this predicted structure, as 
well  as  to  determine if a  shortened version of 2'-amino 
RNA No.  1 could be made that would still bind MA20, a 
series of truncated RNAs were generated and tested for an- 
tibody binding (Fig. 2  B).  These shortened RNAs ranged 
in size  from 34  to  83  nts; however,  only the  83-nt long 
version of 2'-amino RNA  No,  1  retained the  ability to 
bind MA20. Thus, 2'-amino RNA No.  1 (originally 86 nt 
long) could not be shortened to any significant extent and 
still adopt the structure recognized by the antibody. Unfor- 
tunately, this result does not strongly support or refute the 
working model shown in Fig 2 A, but it did underscore the 
need  to  use  the  nearly full-length 83-nt  long  2'-amino 
RNA No.  1 in the following experiments. 
To investigate the structural significance of the 2'-amino 
groups on the pyrimidine nucleotides, selected RNA No. 1 
was generated with 2'-hydroxyl pyrimidines and tested for 
binding to the MA20 antibody. As shown in Fig. 2  C, al- 
teration  of the  2'  position  disrupted  the  interaction be- 
tween RNA  No.  1 and MA20.  Similarly, the  2'  position 
appears to be critical for binding of our selected unmodi- 
fied RNA  (18)  to MA20. Changing the 2' position on the 
pyrimidines of this RNA from hydroxyls to aminos yielded 
a modified RNA that did not bind MA20 (Fig. 2  C). Thus, 
the  2'  position on both selected RNAs appears to be im- 
portant for proper RNA folding and MA20 binding. 
To  estimate the  equilibrium Kd for the  interaction be- 
tween 2'-amino RNA No.  1 and MA20, a gel retardation 
assay  was  used  (Fig.  3  A).  Trace  amounts of radiolabeled 
RNA were incubated with increasing amounts of antibody 
and  complexes  separated  on  nondenaturing  acrylamide 
gels.  The  same  apparent K a of,'o30  nM was  detected  at 
three  different  concentrations of 2'-amino RNA  No.  1 
(Fig.  3  B).  Thus,  selected  2'-amino RNA  No.  1  binds 
fairly avidly to the MA20 antibody. 
Even though the 2'-amino RNA No.  1 specifically and 
avidly binds MA20, this decoy would be of little therapeu- 
Figure 2.  Structural analysis  of 2'-amino RNA No.  l. (A) Predicted 
secondary structure of2'-amino RNA No. 1. Nucleotides  shown in plain 
letters originate from the fixed flanking  sequences  found in the RNA li- 
brary. The 34 nts shown in bold indicate the sequence selected from'the 
randomized region of the RNA library that is present in 2'-amino RNA 
No. 1. U and C represent 2'-amino U and 2'-amino C. Every 10th nt of 
the RNA is numbered. (B) Most of2'-amino RNA No. 1 is required for 
binding to MA20. Truncated versions of 2'-amino RNA No.  1 were 
transcribed and tested for binding to MA20. Tested derivatives  contain 83 
nts of2'-amino RNA No. 1 (nts 1-83; sample I), the 34 nts selected RNA 
sequence (nts 25-58; sample II), 34 nts of the RNA (nts 20-53; sample 
111), 48 nts of the RNA (nts 7-54; sample IV), or 70 nts of the RNA (nts 
5-74;  sample V).  The  RNAs  (2.5 nM)  were incubated with normal 
mouse IgGs (lane b, 1{}0 nM) or MA20 (lane  c, 10{t nM). The antibody- 
RNA complexes were imnmnoprecipitated  and analyzed  on an 8% poly- 
acrylamide gel with urea. Lane a contains  one-fifth  of the amount of radio- 
labeled RNA that was incubated with the antibody. (C) The 2' position 
on the pyrimidine of the selected RNAs is important for antibody bind- 
ing. Internally  radiolabeled  RNAs (2.5 nM) were incubated with normal 
mouse IgGs (lane 2, 125 nM) or MA20 (lane 3, 125 nM). RNAs immu- 
noprecipitated by these antibodies were electrophoresed on a 6"/,, poly- 
acrylamide gel with urea. Lane 1 contains  one fifth of the amount of input 
RNA that was used in the immunoprecipitation  reaction. The 2'-amino 
RNA No. 1 was made with either 2'-amino pymnidines  (NHi/NH2*) or 
2'-hydroxyl pyrinlidines (NH2/OH*). The 2'-hydroxyl RNA  No.  9, 
which we previously described (18), was made with either 2'-hydroxyl 
pyrimidines  (OH/OH*) or 2'-amino pyrimidines  (OH/NH2*). 
tic  utility if the  RNA  is  quickly degraded  by serum nu- 
cleases.  Therefore, the stability of the 2'-amino RNA No. 
1 in serum was measured  (Fig.  4).  In  10%  human sermn, 
RNA  with  2'-hydroxyl  groups  (unmodified RNA)  was 
318  A Decoy RNA against Autoantibodies Figure 3.  Determining the binding at~nity between the selected 2'-amino 
RNA No. 1 and MA20.  (A) Internally radiolabeled 2'-amino RNA No. 
1 (200 pM)  was incubated  with normal  mouse  IgGs (lane  1, 125 riM) or 
decreasing amounts  of MA20 (lanes 2-12, 125-0 nM). The MA20-RNA 
complexes were separated from unbound RNAs by a gel mobility shift as- 
say performed on a 4% nondenaturing  polyacrylamide gel. (B) Three dif- 
ferent  concentrations  of internally  radiolabeled  2'-amino  RNA  No.  1 
were incubated  with the increasing amounts  of the MA20 antibody,  and 
the MA20-RNA complexes  were analyzed as described in A. The per- 
centage of RNA bound to MA20 was calculated by determining  the frac- 
tion of radioactivity present in the MA20--RNA complexes. A maximum 
of 40-50%} of RNA formed MA20-RNA complexes,  even in the pres- 
ence of extremely high concentration  of MA20.  Thus,  plotted  numbers 
have  been  normalized  to  that  amount.  [[], 50  pM  RNA; O,  100  pM 
RNA; dx, 200 pM RNA. 
rapidly  degraded  by  serum  nucleases  (tl/2  r  s).  In  con- 
trast,  2'-amino RNA  No.  1 was resistant to nuclease degra- 
dation with most  of the RNA  remaining full-length,  even 
after 24  h  of incubation.  In the  presence  of 10%  fetal bo- 
vine  serum,  this  difference  in  stability  was  even  greater. 
Once again,  2'-amino RNA  No.  1 was refractory to serum 
nucleases  with  most  of the  RNA  remaining  intact,  even 
after  24  h  of incubation,  while  most  of the  unmodified 
RNA  was  totally degraded by 5  s.  Similar results  were ob- 
tained  when  RNAs  were  incubated  in  100%  serum  (data 
not shown).  Therefore, 2'-amino RNA  No.  1 is more than 
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Figure 4.  Stability of selected 2'-amino RNA in human serum  (/t) or 
fetal bovine serum  (B). Internally radiolabeled selected RNA No. 9 (18) 
containing  2'-hydroxyl pyrimidines  (OH,  10 nM)  or RNA No.  1 con- 
taining  2'-amino pyrimidines  (NH2,  10 nM) were incubated  at 37~  in 
200  Ixl of PBS containing  10% serum.  Aliquots  (20  p,1) of the reaction 
were  removed at  the  times  indicated,  quenched  with  5  ~1  of 0.5  M 
EDTA, phenol extracted,  and fractionated  on a 10% polyacrlyamide  gel 
with urea (s, seconds; m, minutes; h, hours). 
10,000-fold  more  stable  in  serum  than  unmodified  RNA, 
confirming  previously  published  results  describing  the 
nuclease  resistance  of 2'-amino-substituted  RNA  (17,  20- 
22,  27). 
2'-Amino  RNA  No.  1  Blocks  MA20  Binding  to  and 
Downmodulation  of  Insulin  Receptors on  Human  Lympho- 
cytes.  To determine  if selected 2'-amino RNA  No.  1 can 
specifically  inhibit  MA20  binding  to  insulin  receptors  on 
the  surface  of  human  lymphocytes,  we  incubated  IM-9 
cells with the MA20  antibody in the presence  of 2'-amino 
RNA  No.  1  or  a  nonspecific  RNA  competitor.  MA20 
binding was  then  quantitated  by the  addition  of a  second- 
ary  goat  anti-mouse  PE-conjugated  antibody  and  subse- 
quent analysis  of stained  cells via FACS  |  As shown in Fig. 
5 A, addition of the original RNA  pool as a competitor did 
not affect the binding  of MA20  to  IM-9  cells. Addition  of 
selected 2'-amino  RNA  No.  1,  however,  greatly inhibited 
MA20  binding  to  these  cells.  Fluorescent staining  of IM-9 
cells  was  reduced  by  almost  95%  when  2'-amino  RNA 
No.  1  was  used  as  the  competitor.  In  contrast,  selected A 
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Figure 5.  2'-amino RNA No.  l inhibits MA20 binding to insulin receptors on IM-9 cells. The mAbs MA20 (50 ng) (A) or 83-7 (B) were preincu- 
bated in buffer alone or with unselected pool RNA (10 IxM), or selected 2'-amino RNA No. 1 (10 p,M) as competitors. Then, these antibody mixtures 
were incubated with 5 ￿  10  4 IM-9 cells and antibody binding was monitored by FACS  |  analysis,  as described in the Materials and Methods. IM-9 cells 
were stained with the lgG2b or IgG1 isotypic control antibodies to set the counting gates for staining with the MA20 or the 83-7 antibodies, respectively. 
The percentage of cells found in gate M1 is shown at the top of each histogram. 
2'-amino RNA  No.  1 did not interfere with the staining of 
IM-9 cells by a  different mAb,  called 83-7,  which recog- 
nizes a different epitope on the human insulin receptor (26, 
31,  32,  and  Fig.  5  /3).  Therefore,  2'-amino RNA  No.  1 
can specifically inhibit MA20 binding to its normal antigen 
(the  insulin  receptor),  suggesting  that  this  RNA  decoy 
binds near the combining site on the antibody. 
Once we had ascertained that 2'-amino RNA  No.  1 was 
fairly  stable in serum and that it could block MA20 binding 
to the insulin receptors expressed on IM-9 cells in serum- 
free  conditions,  we  wanted  to  determine  if this  decoy 
RNA  could  protect  cells  from  MA20  in  culture  media 
containing serum. Incubation of IM-9 cells with the MA20 
antibody has been shown to cause a dose- and time-depen- 
dent decrease in the number of insulin receptors present on 
the  surface  of these  cells  (33).  This process,  termed  anti- 
genic  downregulation,  can  be  easily monitored  by deter- 
mining the ability of the cells to bind 12+I-insulin (33).  To 
determine  if 2'-amino  RNA  No.  1  could  protect  cells 
from  the  effects  of MA20  and  inhibit antibody-mediated 
downregulation  of insulin receptor expression,  IM-9  cells 
were incubated with MA20 in the presence or absence of 
U-amino RNA  No.  1. As shown in Fig. 6 A, a nonspecific 
RNA  competitor,  such  as  the  original  2'-amino  RNA 
pool, could not inhibit MA20-mediated downregulation of 
insulin  receptor  expression.  However,  decoy  2'-amino 
RNA  No.  1 protected IM-9 cells from MA20 and inhibited 
antigenic downregulation by 75%.  Furthermore, 2'-amino 
RNA  No.  1-mediated inhibition of antigenic downregula- 
tion was dose dependent with an EDs0 of~0.6  IzM (Fig. 6 
B). A  maximum inhibition of 80-90% was obtained at the 
highest  doses  tested.  Thus,  this  nuclease-resistant  decoy 
RNA  can  protect  cells from  the  MA20  antibody  in  the 
presence of serum nucleases. 
2'-Amino RNA  No.  1 Inhibits Autoantibody-mediated, but 
not Insulin-mediated, Downregulation of Insulin  Receptor Ex- 
pression.  Because  MA20  naturally  recognizes  the  main 
immunogenic  epitope  on  the  insulin  receptor  (23)  that 
elicits autoantibodies in  patients with  severe insulin resis- 
tance type B  (24--26), we wanted to determine if2'-amino 
320  A Decoy RNA against Autoantibodies Figure 6.  2'-amino RNA No. 1 inhibits MA20-mediated downmodu- 
lation of insulin receptor expression on human lymphocytes in culture. 
(A) IM-9 cells were incubated in complete cell culture media containing 
no antibody (w/o Ab), normal mouse IgGs (mlgs, 1 nM), MA20 (1 nM), 
MA20 (1 nM) plus 2'-amino pool RNA (3 btM), or MA20 (1 nM) plus 
2'-amino  RNA 461  (3 IxM). Downmodulation of insulin receptor ex- 
pression was assayed  by f2Sl-insulin binding, as described in the Materials 
and Methods. Values are expressed as a percentage of the downmodula- 
tion engendered by the MA20 antibody (1  nM) alone (percent of anti- 
genic modulation). Values shown are averages -+ SD of measurements 
performed in triplicate. (/3) IM-9 cells were incubated in culture media 
containing MA20 (1 nM) and increasing amounts of 2'-amino RNA No. 
1,  and  downmodulation of insulin receptor expression was assayed as 
above. 
R.NA No.  1 would also bind any of the antiinsulin receptor 
autoantibodies from these patients.  Therefore, an irmnuno- 
precipitation  experiment was performed using radiolabeled 
2'-amino  RNA  No.  1  and  antibodies  from  sera  of three 
different patients  called B7, B10, and Bd. As shown in Fig. 
7 A, all three of the autoimmune sera were found to contain 
antibodies  that can bind  and immunoprecipitate  2'-amino 
RNA  No.  1.  In contrast,  the  selected RNA  was not pre- 
cipitated by normal mouse IgGs, the 83-7 mAb (26, 31, 32), 
or antibodies  from normal human serum.  Thus,  2'-amino 
RNA  No.  1  appears  to  specifically cross-react with  some 
fraction of the patients' autoantibodies. 
This  result  raised  the  intriguing possibility  that  selected 
2'-amino RNA  No.  1 may resemble  or mimic  the  struc- 
ture  of the  main  antigenic  epitope  on  the  human  insulin 
receptor. If this were indeed the case, then one would pre- 
dict that such a mimotope should be able to block a signifi- 
cant fraction of the patient autoantibodies from binding in- 
sulin  receptors  on the  surface  of human  cells.  To  test  this 
hypothesis, we evaluated the ability of2'-amino RNA No. 
1 to protect cells  from the effects of the three autoimmune 
sera,  B7,  B10,  and Bd.  Incubation of IM-9 cells  with  the 
patient  sera was  shown  to  cause  a  dose-  and time-depen- 
dent  decrease in  insulin  receptor  expression,  as monitored 
by the subsequent inability of these cells  to bind 125I-insulin 
(data not shown). Addition of  selected 2'-amino RNA No. 
1 protected the cells  from the autoantibodies in the patient 
sera and inhibited downmodulation of insulin receptor ex- 
pression by "'54% with B7,  75% with B10,  and 40% with 
Bd (Fig.  7  B).  Furthermore,  2'-amino  RNA  No.  1  pro- 
tected cells from the autoantibodies in B10 serum as effec- 
tively as it protected  cells  from the MA20  mAb.  By con- 
trast,  addition  of the  original  2'-amino  pool  RNA  as  a 
competitor did not inhibit  the  antigenic  downmodulation 
engendered  by  the  patient  sera,  indicating  that  2'-amino 
RNA  No.  1 specifically blocks the antiinsulin  receptor au- 
toantibodies in these sera.  In addition, 2'-amino RNA No. 
1 did not inhibit insulin-induced loss (34)  of insulin recep- 
tors on IM-9 cells (Fig. 7  B). Thus, 2'-amino RNA  No.  1 
can block an autoimmune response to the insulin receptor 
without  impeding  insulin  binding  to  its  receptor.  Finally, 
to determine  how effectively 2'-amino RNA  No.  1 could 
protect  IM-9  cells  from the  autoantibodies  present  in  the 
serum  of patient  B10,  a  dose-escalation  experiment  was 
performed.  As shown in  Fig.  7  C,  at high concentrations, 
2'-amino RNA  No.  1 can block ,'~70-80% of the B10 au- 
toantibodies responsible for insulin receptor loss.  Such pro- 
tection is dose dependent with an EDs0 of"~  p~M  (Fig. 
7  C).  Therefore,  2'-amino RNA  No.  1 can protect IM-9 
cells  from a  significant  fraction  of the  antiinsulin  receptor 
autoantibodies present in a patient with severe insulin resis- 
tance. 
Discussion 
Previously, we and others have described the isolation of 
small  RNA  molecules  that  avidly bind  specific  antibodies 
and block them from binding their natural antigens in vitro 
(13,  14,  18). These observations have led to the speculation 
that  such  RNA  decoys  may  be  useful  as  therapeutics  to 
combat autoimmune responses in patients. While these ini- 
tial studies allowed for much conjecture,  they were unable 
to critically test many aspects of this decoy hypothesis. Spe- 
cifically, the short half-life of RNAs in the presence of se- 
321  Lee and SuHenger Figure  7.  2'-amino RNA No.  1 can act as a decoy for autoantibodies 
against the human insulin receptor.  (A) 2'-amino RNA No. I  is recog- 
nized by human autoantibodies in sera from patients with severe insulin 
resistance type B. Radiolabeled 2'-amino RNA No. 1 (2.5 nM) was im- 
munoprecipitated with normal mouse IgGs (lane 1, 100 nM), MA20 (lane 
2, 100 nM), the 83-7 mAb (lane 3, 3 Ftl), normal human sera (lane 4, 50 
p,1), or three autoimmune patients' sera (lane 5, serum B7; lane 6, serum 
B10; lane 7, serum Bd, 50 Ftl each). Bound RNA was eluted and electro- 
phoresed on a 6% polyacrylamide gel with urea. (B) 2'-amino RNA No. 
1 inhibits  autoantibody-mediated  downmodulation of insulin receptor 
expression. IM-9 cells were  incubated  in complete  cell culture  media 
containing  MA20 (1 riM), normal human sera (1 p,1), B7 patient sera (1 p~l 
of 1:25 dilution), B10 patient sera (l p~l of 1:12 dilution), Bd patient sera 
(1  I*1), or insulin (1  p.M) that had been preincubated  in the absence of 
RNA competitors (a) or with either 3 laM pool RNA (b), or 3 p~M se- 
lected RNA No. 1 (c; see Materials and Methods for details). Downmod- 
ulation of insulin receptor expression was assayed by 12sI-insulin  binding, 
as previously described. Values are expressed as a percentage of the down- 
rum nucleases made  it impossible to  determine if a  decoy 
RNA  could protect human cells from a patient's autoanti- 
bodies. To address this shortcoming, we performed the ex- 
periments described herein. 
In  vitro  selection  techniques  (4,  35,  36)  were  used  to 
identify  a  small,  nuclease-resistant  RNA  molecule  that 
binds to a  mouse mAb, called MA20, which naturally rec- 
ognizes the main autoantigenic epitope on the human insu- 
lin  receptor.  To  yield  nuclease-resistant  RNA,  selection 
was performed using a modified RNA  pool containing py- 
rimidine nucleotides with  2'-amino groups  (27).  The  se- 
lected RNA  binds to  the MA20  antibody specifically (Fig. 
1)  and  with  high  affinity  (Fig.  3).  The  presence  of such 
2'-amino groups increased the stability of the RNA  in se- 
rum by more than 10,000-fold, as compared to unmodified 
RNA  (Fig. 4). This selected RNA  can serve as a decoy and 
block MA20 binding to insulin receptors  on the surface of 
human lymphocytes  (Fig.  5).  This RNA  can  also  protect 
cells  from  the  MA20  antibody and prevent  MA20-medi- 
ated  downmodulation of insulin receptor  expression  (Fig. 
6).  Furthermore,  this  selected  RNA  cross-reacts  with  au- 
toantibodies from three patients with extreme insulin resis- 
tance (type B) and can inhibit autoantibody-mediated down- 
modulation of insulin receptor expression without impeding 
insulin binding to  its  receptor  (Fig.  7).  Thus,  a  nuclease- 
resistant decoy RNA  can protect human cells from patient 
autoantibodies. 
The  three  sets  of human autoimmune sera contain anti- 
bodies that naturally recognize the same region of the hu- 
man insulin receptor  as MA20.  This immunogenic region 
is contained within amino acids 450-601  of the ci subunit 
of insulin receptor and appears  to  elicit the majority of au- 
toantibodies  in  patients  with  extreme  insulin  resistance 
(26).  Since  small  RNAs,  selected  to  bind  MA20,  cross- 
react  with autoantibodies that  recognize  the  same  epitope 
on insulin receptor as MA20 (18 and Fig. 7 A), we hypoth- 
esized that such selected RNAs may mimic the structure of 
the  receptor  that  is bound by  the  antibodies.  Such  RNA 
rnimotopes would be expected to be able to block a signif- 
icant fraction of a patient's autoantibodies even though the 
patient's immune response to  the antigenic epitope  would 
probably  be  oligoclonal.  As  shown  in  Fig.  7  B,  selected 
2'-amino RNA  No.  1 can significantly block the action of 
autoantibodies from three different patients, but to varying 
degrees.  These  different levels of inhibition may be caused 
by differences in the patient's immune response  to  the  in- 
modulation engendered by the MA20 antibody  (1  nM; percent  of anti- 
genic modulation), and the dilutions of patient sera used were chosen be- 
cause they  engender  similar levels of downmodulation as  1 nM MA20 
(see Materials and Methods for details). Values shown are means +-SD of 
three measurements obtained from three separate experiments. (C) IM-9 
cells were incubated in culture media containing  BI0 patient sera (1  p~l of 
1:12 dilution)  and increasing amounts  of 2'-amino RNA  No.  1,  and 
downmodulation of insulin  receptor expression was assayed as above. Val- 
ues are expressed as the percentage of the downmodulation engendered 
by B10 patient sera alone. 
322  A Decoy RNA against Autoantibodies sulin receptor,  with  certain patients  making a greater per- 
centage of their autoantibodies  against the main immuno- 
genic region than others.  In the best case, the RNA  decoy 
appears to be able to inhibit the downmodulation of insulin 
receptor expression that is engendered by the autoantibod- 
ies from patient B10, as effectively as it inhibits the MA20 
mAb  (Fig.  7,  B  and  C).  Thus,  remarkably  a  single RNA 
decoy can apparently impede a significant fraction of a pa- 
tient's autoantibodies from binding their targeted self-anti- 
gen.  This  result suggests  that  one  or a few selected  decoy 
RNAs may be able  to block autoimmune responses,  even 
though such responses are probably oligoclonal in nature. 
The decoy RNA does not appear to inhibit insulin bind- 
ing to and down-regulation of its receptor on the surface of 
human lymphocytes  (Fig.  7  B).  This  observation  that  the 
decoy RNA  selectively blocks antibodies is consistent with 
the  hypothesis that  the  RNA  mimics  the  structure  of the 
immunogenic  epitope  on the  insulin  receptor.  MA20  has 
been shown to bind the receptor near but not at the site of 
insulin binding  (23).  Thus,  a decoy RNA  that structurally 
resembles  the  antigenic  region  of  the  insulin  receptor 
would not be expected to interact with insulin. 
Our results  suggest that designer decoy RNAs may be- 
come useful reagents to inhibit autoimmune responses.  To 
be of any therapeutic value however, more effective RNA 
decoys will probably be required.  To isolate  an RNA  de- 
coy that can block a greater fraction of autoantibodies from 
a variety of patients,  in vitro  selections  can be performed 
using a pool of human autoantibodies.  Furthermore,  it re- 
mains  to be  determined  if nuclease-resistant  decoy RNAs 
can block immune responses in animals or if they will elicit 
immune responses rather than block them. 
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